Synergistic Effects of Green Nanoparticles on Antitumor Drug Efficacy in Hepatocellular Cancer DOI Creative Commons
Mirela Claudia Rîmbu, Liliana Popescu, Mirela Mihăilă

и другие.

Biomedicines, Год журнала: 2025, Номер 13(3), С. 641 - 641

Опубликована: Март 5, 2025

Background/Objectives: Cancer remains one of the leading causes mortality worldwide. Despite significant advancements in treatment strategies and drug development, survival rates remain low adverse effects conventional therapies severely impact patients’ quality life. This study evaluates therapeutic potential plant-derived extracts hepatocellular carcinoma treatment, with a focus on minimizing side while enhancing efficacy. Methods: research investigates vitro synergistic effect silver bio-nanoparticles synthesized from Clematis vitalba, Melissa officinalis, Taraxacum officinale (Clematis vitalbae extractum—CVE, Melissae extractum—ME, Taraxaci extractum—TE) combination liver cancer drugs, sunitinib (SNTB) imatinib (IMTB), HepG2 (human carcinoma) HUVEC umbilical vein endothelial) cell lines. The nanoparticles (AgNPs) were characterized using UV-Vis spectroscopy, dynamic light scattering (DLS), zeta analysis, scanning electron microscopy (SEM). antitumor evaluated through viability assays after 24 48 h exposure, additional cytotoxicity tests cells. Results: Results indicated that officinalis-derived (ME AgNPs) vitalba extract (CVE significantly reduced viability. Their efficacy improved when combined (SNTB + ME AgNPs 1:1 vs. SNTB: 20.01% 25.73%, p = 0.002; IMTB IMTB: 17.80% 18.08%, 0.036; SNTB CVE 18.73% 0.000; 1:2 26.62% 41.00%, 0.018; 12.99% 0.001). exhibited similar to its nanoparticle formulation but did not exceed alone at h. Selectivity index assessments confirmed AgNPs-based formulations improve selectivity Among tested extracts, demonstrated strongest effect, synthetic drugs (CI < 1). TE (5% EtOH) also consistent synergy high doses, provided broad-range synergy, making it suitable for dose-escalation strategies. Conclusions: These findings underscore nanoparticle-based targeted kinase inhibitors such as imatinib. Future should vivo validation clinical trials confirm these findings.

Язык: Английский

Synergistic Effects of Green Nanoparticles on Antitumor Drug Efficacy in Hepatocellular Cancer DOI Creative Commons
Mirela Claudia Rîmbu, Liliana Popescu, Mirela Mihăilă

и другие.

Biomedicines, Год журнала: 2025, Номер 13(3), С. 641 - 641

Опубликована: Март 5, 2025

Background/Objectives: Cancer remains one of the leading causes mortality worldwide. Despite significant advancements in treatment strategies and drug development, survival rates remain low adverse effects conventional therapies severely impact patients’ quality life. This study evaluates therapeutic potential plant-derived extracts hepatocellular carcinoma treatment, with a focus on minimizing side while enhancing efficacy. Methods: research investigates vitro synergistic effect silver bio-nanoparticles synthesized from Clematis vitalba, Melissa officinalis, Taraxacum officinale (Clematis vitalbae extractum—CVE, Melissae extractum—ME, Taraxaci extractum—TE) combination liver cancer drugs, sunitinib (SNTB) imatinib (IMTB), HepG2 (human carcinoma) HUVEC umbilical vein endothelial) cell lines. The nanoparticles (AgNPs) were characterized using UV-Vis spectroscopy, dynamic light scattering (DLS), zeta analysis, scanning electron microscopy (SEM). antitumor evaluated through viability assays after 24 48 h exposure, additional cytotoxicity tests cells. Results: Results indicated that officinalis-derived (ME AgNPs) vitalba extract (CVE significantly reduced viability. Their efficacy improved when combined (SNTB + ME AgNPs 1:1 vs. SNTB: 20.01% 25.73%, p = 0.002; IMTB IMTB: 17.80% 18.08%, 0.036; SNTB CVE 18.73% 0.000; 1:2 26.62% 41.00%, 0.018; 12.99% 0.001). exhibited similar to its nanoparticle formulation but did not exceed alone at h. Selectivity index assessments confirmed AgNPs-based formulations improve selectivity Among tested extracts, demonstrated strongest effect, synthetic drugs (CI < 1). TE (5% EtOH) also consistent synergy high doses, provided broad-range synergy, making it suitable for dose-escalation strategies. Conclusions: These findings underscore nanoparticle-based targeted kinase inhibitors such as imatinib. Future should vivo validation clinical trials confirm these findings.

Язык: Английский

Процитировано

0